Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Poly (ADP-ribose) polymerase inhibitors (PARPis) benefit ovarian cancer patients with BRCA1/2 mutations. Specific mutation locations and types, particularly missense mutations, influence treatment response to PARPi, with certain domains showing greater efficacy.
Area Of Science
- Oncology
- Genetics
- Pharmacology
Background
- Limited knowledge exists on how BRCA1/2 mutation type and location affect response to poly (ADP-ribose) polymerase inhibitors (PARPis) as a single agent in ovarian cancer.
- Investigating these associations is crucial for personalized treatment strategies.
Purpose Of The Study
- To investigate the effectiveness of PARPi based on functional domains (FD) and mutation types of BRCA1/2 genes in ovarian cancer patients.
- To identify specific BRCA1/2 mutation characteristics associated with optimal response to PARPi therapy.
Main Methods
- A multicenter, real-world study retrospectively analyzed BRCA1/2-mutated ovarian cancer patients receiving olaparib maintenance.
- Data were compared with historical controls who did not receive olaparib and analyzed based on functional domains (FD) of BRCA1/2 mutations.
- Progression-free survival was the primary endpoint, calculated from the last platinum-based treatment.
Main Results
- Poly (ADP-ribose) polymerase inhibitors (PARPis) demonstrated efficacy in the overall BRCA1/2-mutated ovarian cancer population.
- Patients with BRCA1 mutations in the RING or BRCT domains and BRCA2 mutations in the RAD51-BD showed significant benefits.
- Missense mutations, particularly p.(Ala1708Glu) in BRCA1's BRCT domain, were associated with the most substantial advantage from PARPi maintenance.
Conclusions
- BRCA1/2-mutated ovarian cancer patients benefit from olaparib, with response varying by mutation type and functional domain.
- Targeting specific mutation locations within BRCA1 (RING, BRCT) and BRCA2 (RAD51-BD) can optimize PARPi therapy.
- Maintenance therapy with PARPi offers significant advantages for patients with missense mutations, especially those with the p.(Ala1708Glu) variant.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...